ADVANCED
PATHOPHARMACOLOGICAL
FOUNDATIONS FINAL EXAM
QUESTIONS AND ANSWERS
1. Which cellular process involves the programmed activation of caspases leading to DNA
fragmentation and cell death without eliciting an inflammatory response?
A. Necrosis
B. Pyroptosis
C. Autophagy
D. Apoptosis
Answer: D
Conceptual Explanation: Apoptosis is a regulated, programmed cell death involving
caspases. Unlike necrosis, it does not cause inflammation because the cell membrane
remains intact until phagocytosis occurs.
,2. In the Renin-Angiotensin-Aldosterone System (RAAS), which enzyme is primarily
responsible for converting Angiotensin I to the potent vasoconstrictor Angiotensin II?
A. Angiotensin-Converting Enzyme (ACE)
B. Renin
C. Aldosterone synthase
D. Chymase
Answer: A
Conceptual Explanation: ACE, primarily found in the pulmonary vascular endothelium,
converts Angiotensin I to Angiotensin II.
3. A patient with chronic obstructive pulmonary disease (COPD) develops secondary
polycythemia. What is the physiological driver for this adaptation?
A. Decreased breakdown of red blood cells in the spleen
B. Increased production of erythropoietin by the kidneys in response to chronic hypoxemia
C. Hypercapnia-induced stimulation of the bone marrow
D. Increased iron absorption in the gastrointestinal tract
Answer: B
Conceptual Explanation: Chronic hypoxemia stimulates the kidneys to release
erythropoietin, which signals the bone marrow to produce more red blood cells to increase
oxygen-carrying capacity.
, 4. Which mechanism best describes the action of HMG-CoA reductase inhibitors (Statins) in
managing dyslipidemia?
A. Inhibition of cholesterol absorption in the small intestine
B. Activation of PPAR-alpha to increase fatty acid oxidation
C. Sequestration of bile acids in the gut
D. Competitive inhibition of the rate-limiting enzyme in hepatic cholesterol synthesis
Answer: D
Conceptual Explanation: Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in
the mevalonate pathway of cholesterol synthesis, leading to increased LDL receptor
expression on hepatocytes.
5. A 55-year-old male presents with a sudden onset of severe joint pain and swelling in his
great toe. Microscopic analysis of synovial fluid reveals needle-shaped, negatively
birefringent crystals. What is the underlying pathophysiology?
A. Calcium pyrophosphate deposition
B. Autoimmune destruction of articular cartilage
C. Hyperuricemia leading to monosodium urate crystal deposition
D. Bacterial infection of the joint space
Answer: C
PATHOPHARMACOLOGICAL
FOUNDATIONS FINAL EXAM
QUESTIONS AND ANSWERS
1. Which cellular process involves the programmed activation of caspases leading to DNA
fragmentation and cell death without eliciting an inflammatory response?
A. Necrosis
B. Pyroptosis
C. Autophagy
D. Apoptosis
Answer: D
Conceptual Explanation: Apoptosis is a regulated, programmed cell death involving
caspases. Unlike necrosis, it does not cause inflammation because the cell membrane
remains intact until phagocytosis occurs.
,2. In the Renin-Angiotensin-Aldosterone System (RAAS), which enzyme is primarily
responsible for converting Angiotensin I to the potent vasoconstrictor Angiotensin II?
A. Angiotensin-Converting Enzyme (ACE)
B. Renin
C. Aldosterone synthase
D. Chymase
Answer: A
Conceptual Explanation: ACE, primarily found in the pulmonary vascular endothelium,
converts Angiotensin I to Angiotensin II.
3. A patient with chronic obstructive pulmonary disease (COPD) develops secondary
polycythemia. What is the physiological driver for this adaptation?
A. Decreased breakdown of red blood cells in the spleen
B. Increased production of erythropoietin by the kidneys in response to chronic hypoxemia
C. Hypercapnia-induced stimulation of the bone marrow
D. Increased iron absorption in the gastrointestinal tract
Answer: B
Conceptual Explanation: Chronic hypoxemia stimulates the kidneys to release
erythropoietin, which signals the bone marrow to produce more red blood cells to increase
oxygen-carrying capacity.
, 4. Which mechanism best describes the action of HMG-CoA reductase inhibitors (Statins) in
managing dyslipidemia?
A. Inhibition of cholesterol absorption in the small intestine
B. Activation of PPAR-alpha to increase fatty acid oxidation
C. Sequestration of bile acids in the gut
D. Competitive inhibition of the rate-limiting enzyme in hepatic cholesterol synthesis
Answer: D
Conceptual Explanation: Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in
the mevalonate pathway of cholesterol synthesis, leading to increased LDL receptor
expression on hepatocytes.
5. A 55-year-old male presents with a sudden onset of severe joint pain and swelling in his
great toe. Microscopic analysis of synovial fluid reveals needle-shaped, negatively
birefringent crystals. What is the underlying pathophysiology?
A. Calcium pyrophosphate deposition
B. Autoimmune destruction of articular cartilage
C. Hyperuricemia leading to monosodium urate crystal deposition
D. Bacterial infection of the joint space
Answer: C
